ID

35168

Beschrijving

Study ID: 107022 Clinical Study ID: 107022 Study Title: A phase IIb, controlled, randomised, multicenter, single blind study to demonstrate the Non-Inferiority of the low dose influenza vaccine with or without adjuvant AS03 compared with Fluarix (GlaxoSmithKline Biologicals) administered intramuscularly in elderly >= 60 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00321373 Study Link: https://clinicaltrials.gov/ct2/show/NCT00321373 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Candidate Influenza Vaccine GSK1247446A - 2 different formulations Trade Name: FluarixTM Study Indication: Influenza The purpose of his form is to document if a blood sample for HI antibody determination has been taken. Visit 1: Day 0, Pre vaccination Visit 2: Day 21, Post vaccination 1 Phone contact: Day 30, post vaccination 1 Visit 3: Day 180, post vaccination 1 Visit 1 and 2 are part of the study: "Demonstration of the Non-Inferiority of the Low Dose Influenza Vaccine Compared with Fluarix NCT00321373" This study is a LONG-TERM FOLLOW-UP to the PREVIOUS STUDY 107022 (FLU-LD-001).

Link

https://clinicaltrials.gov/ct2/show/NCT00321373

Trefwoorden

Versies (3)

1. 13-02-19 13-02-19 -
2. 20-02-19 20-02-19 - Sarah Riepenhausen
3. 25-02-19 25-02-19 - Sarah Riepenhausen

Houder van rechten

GlaxoSmithKline

Geüploaded op

20 februari 2019

DOI

Voor een aanvraag inloggen.

Licentie